<DOC>
	<DOCNO>NCT02865304</DOCNO>
	<brief_summary>The purpose present study prospectively evaluate efficacy safety endostar , recombinant product endostatin , combine taxane-based regimen HER-2 negative metastatic breast cancer ( MBC ) patient .</brief_summary>
	<brief_title>The Efficacy Safety Endostar Combined With Taxane-based Regimens HER-2-negative MBC Patients</brief_title>
	<detailed_description>Endostar recombinant product endostatin , endogenous inhibitor angiogenesis . Animal study show endostatin capable block proliferation organization endothelial cell new blood vessel vitro inhibit angiogenesis growth primary tumor secondary metastasis . Regarding breast cancer , vivo study show combination paclitaxel P125A-endostatin inhibit mammary cancer growth , delay onset multifocal mammary adenocarcinoma , decrease tumor angiogenesis , increase survival treated mouse prevention model , inhibit lung lymph node metastasis intervention model . Moreover , prospective , randomize , control , phase II neoadjuvant trial , combination rh-endostatin chemotherapy produce high tumor response rate without increase toxicity breast cancer patient . Considering promise data , prospective study conduct evaluate efficacy safety endostar combine taxane-based regimen HER-2-negative MBC patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>woman age 1870 year histologically confirm MBC document HER2negative tolerate chemotherapy cardiac insufficiency</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>HER-2-negative</keyword>
	<keyword>endostar</keyword>
</DOC>